Immunic to Attend Key Investor Conferences in March

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company focused on developing novel oral therapies for neurologic and gastrointestinal disorders, announced its participation in two significant investor conferences in March. The company will attend the Leerink Partners Global Healthcare Conference from March 8-11, held in Miami. Key executives, including CEO Dr. Daniel Vitt and President Jason Tardio, will engage in a fireside chat and one-on-one investor meetings.

Additionally, Immunic will participate in the Stifel 2026 Virtual CNS Forum from March 17-18. This virtual presence includes a webcast and one-on-one discussions, allowing investors to gain insights into the company's strategic initiatives and clinical developments. Interested parties are encouraged to schedule meetings through official channels.